Search Results - "Nayee, J"

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study

    A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study by Aronne, L J, Tonstad, S, Moreno, M, Gantz, I, Erondu, N, Suryawanshi, S, Molony, C, Sieberts, S, Nayee, J, Meehan, A G, Shapiro, D, Heymsfield, S B, Kaufman, K D, Amatruda, J M

    Published in International Journal of Obesity (01-05-2010)
    “…Objective: To evaluate the efficacy, safety and tolerability of taranabant in obese and overweight patients. Design: Double-blind, randomized,…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    A two-year study to assess the efficacy, safety, and tolerability of taranabant in obese patients: 52 week results

    A two-year study to assess the efficacy, safety, and tolerability of taranabant in obese patients: 52 week results by Proietto, J, Gantz, I, Carr, R.D, Erondu, N, Moreno, M, Suryawanshi, S, Musser, B, Nayee, J, Johnson-Levonas, A.O, Heymsfield, S, Amatruda, J

    Published in International Journal of Obesity (01-05-2008)
    Get full text
    Journal Article
    Save to List
    Saved in:
  3. 3
    A TWO-YEAR STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF TARANABANT IN OBESE PATIENTS: 52 WEEK RESULTS

    A TWO-YEAR STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF TARANABANT IN OBESE PATIENTS: 52 WEEK RESULTS by Carr, R.D., Gantz, I., Erondu, N., Moreno, M., Suryawanshi, S., Musser, B., Nayee, J., Johnson-Levonas, A.O., Heymsfield, S., Amatruda, J.

    Published in Atherosclerosis. Supplements (01-05-2008)
    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: